文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

ART-123与多黏菌素B固定化血液灌流对脓毒症生存结局的获益效应修饰:日本全国注册研究

Beneficial effect modification on survival outcome of sepsis between ART-123 and polymyxin B‑immobilised haemoperfusion: a nationwide Japanese registry study.
PubMed 文献 · Ann Intensive Care · 2020-05-13
一句话结论日本全国注册数据的post hoc分析显示,ART-123与PMX-HP联合使用对脓毒症患者生存结局存在显著的获益效应修饰(调整HR 0.667)。

该研究为日本脓毒症弥散性血管内凝血注册数据的post hoc分析,纳入2350例脓毒症患者,评估ART-123与多黏菌素B固定化血液灌流(PMX-HP)对医院病死率的效应修饰。在未引入乘积项的模型中,ART-123给药与生存结局独立正相关(调整HR 0.834,95%CI 0.695-0.999,P=0.049);引入乘积项后,ART-123与PMX-HP之间存在显著的生存获益效应修饰(调整HR 0.667,95%CI 0.462-0.961,P=0.030)。作者结论认为ART-123的主效应可能对脓毒症患者生存有益,且与PMX-HP联合存在显著获益效应修饰。

要点

  • 在2350例脓毒症患者中,ART-123给药与医院生存结局独立正相关(调整HR 0.834,95%CI 0.695-0.999,P=0.049)。
  • ART-123与PMX-HP联合使用对生存结局存在显著获益效应修饰(调整HR 0.667,95%CI 0.462-0.961,P=0.030)。
  • 该研究为日本脓毒症DIC注册数据的post hoc分析,主要终点为医院病死率。
  • 作者认为ART-123的主效应可能对脓毒症患者生存有益,联合PMX-HP存在显著获益效应修饰。

适用人群与场景

  • 日本42个ICU登记的3195例脓毒症患者中纳入分析的2350例(日本脓毒症弥散性血管内凝血注册研究数据集)。

研究设计与关键结果

  • 研究类型:日本全国注册研究的post hoc分析,纳入2350例脓毒症患者,主要终点为医院病死率。
  • 未引入乘积项的模型中,ART-123给药与生存结局独立正相关(调整HR 0.834,95%CI 0.695-0.999,P=0.049)。
  • 引入乘积项后,ART-123与PMX-HP之间存在显著的生存获益效应修饰(调整HR 0.667,95%CI 0.462-0.961,P=0.030)。

证据类型、等级与局限

  • 证据类型:基于日本全国注册数据的post hoc分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为ART-123给药的主效应可能对脓毒症患者生存结局有益。
  • 作者认为ART-123与PMX-HP联合使用存在显著的获益效应修饰。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although recently published randomised controlled trials did not confirm significant positive effect of ART-123 or polymyxin B‑immobilised haemoperfusion (PMX-HP) on survival outcome, previous studies using a dataset of 3195 patients with sepsis registered at 42 intensive care units throughout Japan revealed significantly reduced mortality following these treatments. A study has suggested the efficacy of combination therapy with ART-123 and PMX-HP; however, it did not evaluate the effect modification between them. We hypothesised that coadministration of ART-123 and PMX-HP has a significant positive effect modification on survival outcome. The purpose of this study was to evaluate the effect modification between ART-123 and PMX-HP treatment on the survival outcome of sepsis using post hoc analysis of the dataset of the Japan Septic Disseminated Intravascular Coagulation registry.

RESULTS: Of the 3195 patients recorded in the registry, 2350 were analysed. The product term between ART-123 and PMX-HP was analysed by the Cox regression model to evaluate significance. The primary outcome of this study was hospital mortality. Although the administration of ART-123 was independently positively associated with survival outcome (adjusted hazard ratio [HR]: 0.834, 95% confidence interval [CI] 0.695-0.999; P = 0.049) in the model prior to the introduction of the product term, a significant effect modification on survival outcome was observed between the administration of ART-123 and PMX-HP treatment (adjusted HR: 0.667, 95% CI 0.462-0.961; P = 0.030).

CONCLUSIONS: The main effect of the administration of ART-123 may be beneficial for survival outcome in patients with sepsis. In addition, a significant beneficial effect modification on survival outcome was observed between the administration of ART-123 and PMX-HP treatment.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Mochizuki K, Mori K, Kamijo H, et al. Beneficial effect modification on survival outcome of sepsis between ART-123 and polymyxin B‑immobilised haemoperfusion: a nationwide Japanese registry study. Ann Intensive Care. 2020. PMID: 32405776. doi:10.1186/s13613-020-00674-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。